Resmed (RMD) FY2012 results: revenue $1.4 billion, up 10.1% on the year
Resmed Inc. (RMD) reported revenue of $1.4 billion for fiscal 2012, the year ended 30 June 2012, up 10.1% on the year before. Net income was $255 million, up 12.3%, and diluted earnings per share $1.71. The figures are the company's own, from the 10-K it filed with the SEC on 8 August 2014.
Revenue
$1.4 billion
+10.1% on the year
FY2009FY2012
Operating margin
21.5%
21.5% a year earlier
FY2009FY2012
Net income
$255 million
+12.3% on the year
FY2009FY2012
Diluted EPS
$1.71
+18.8% on the year
FY2009FY2012
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Revenue
1,369
1,243
1,092
+10.1%
Cost of revenue
548
502
437
+9.2%
Gross profit
821
741
655
+10.7%
Gross margin
60.0%
59.6%
60.0%
Research and development
110
92.0
75.2
+19.3%
Selling, general and administrative
403
372
329
+8.2%
Operating income
294
267
240
+10.3%
Operating margin
21.5%
21.5%
22.0%
Interest expense
4.8
1.8
2.7
+172.2%
Pre-tax income
332
304
261
+9.3%
Income tax
77.1
76.7
70.5
+0.5%
Effective tax rate
23.2%
25.3%
27.1%
Net income
255
227
190
+12.3%
Net margin
18.6%
18.3%
17.4%
Diluted EPS
$1.71
$1.44
$1.23
+18.8%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Operating cash flow
383
283
188
+35.3%
Capital expenditure
47.1
66.6
56.9
-29.2%
Free cash flow
336
217
131
+55.1%
Free cash flow margin
24.6%
17.4%
12.0%
Cash from investing
-102
-76.5
-58.3
Cash from financing
-177
-79.3
-61.1
Depreciation and amortisation
85.9
70.6
61.6
+21.6%
Share-based compensation
30.6
30.8
29.7
-0.7%
Buybacks
393
163
131
+140.4%
Diluted shares, weighted
149m
157m
155m
-5.0%
Shares outstanding at period end
142m
152m
151m
-6.4%
Balance sheet
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Shareholders' equity
1,608
1,731
1,288
-7.1%
Debt
251
100
122
+150.4%
Other liabilities
279
238
217
+17.4%
Total liabilities and equity
2,138
2,069
1,626
+3.3%
Fixed assets
434
462
387
-6.0%
Goodwill
256
235
199
+8.8%
Intangible assets
54.8
47.9
30.9
+14.4%
Securities held for sale or to maturity
n/a
0.0
n/a
Cash and equivalents
810
735
489
+10.1%
Receivables
283
274
227
+3.2%
Inventory
174
201
186
-13.2%
Other assets
125
113
108
+11.0%
Total assets
2,138
2,069
1,626
+3.3%
10-K for the year ended 30 June 2012, filed 8 August 2014: the filing.